Trotabresib
- Generic Name
- Trotabresib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1706738-98-8
- Unique Ingredient Identifier
- K424WH3WU0
- Background
Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
- Associated Conditions
- -
- Associated Therapies
- -
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT06137651
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath